STOCKHOLM, Nov. 2, 2021 /PRNewswire/ -- Calliditas
Therapeutics AB (publ.) publishes the nomination committee's
composition for the AGM in 2022.
The nomination committee, which is appointed in accordance with
the principles adopted by the extraordinary general meeting in
2017, consists of:
- Patrick Sobocki, appointed by Stiftelsen Industrifonden
- Karl Tobieson, appointed by Linc AB
- Pär Sjögemark, appointed by Handelsbanken Fonder
- Elmar Schnee (chairman of the
board of directors)
The nomination committee shall, before the annual general
meeting 2022, prepare a proposal for the election of chairman and
other members of the board of directors, the election of chairman
of the annual meeting, election of auditors, the determination of
fees and matters pertaining thereto.
For more information please visit:
https://www.calliditas.se/en/nomination-committee-2314/
Shareholders who wish to submit proposals to the nomination
committee for the annual general meeting on May 31, 2022, can do so by e-mail to
finance@calliditas.com. Proposals should be submitted to the
nomination committee before April 8,
2022.
For further information, please contact:
Fredrik Johansson, CFO at
Calliditas
Email: fredrik.johansson@calliditas.com
Telephone: +46 703 52 91 90
The information was submitted for publication, through the
agency of the contact person set out above, at 10.00 a.m CET on
November 2, 2021.
About Calliditas Therapeutics
Calliditas Therapeutics is a biopharma company based in
Stockholm, Sweden focused on
identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product candidate, Nefecon, is a proprietary, novel oral
formulation of budesonide, an established, highly potent local
immunosuppressant, for the treatment of adults with the autoimmune
renal disease primary IgA nephropathy (IgAN), for which there is a
high unmet medical need and there are no approved treatments.
Calliditas read out topline data from Part A of its global Phase 3
study in IgAN in November 2020 and,
if approved, aims to commercialize Nefecon in the United States. Calliditas is also planning
to start clinical trials with NOX inhibitors in primary biliary
cholangitis and head and neck cancer. Calliditas is listed on
Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select
Market (ticker: CALT).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-therapeutics--nomination-committee-for-the-agm-2022,c3445127
The following files are available for download:
|
https://mb.cision.com/Main/16574/3445127/1489952.pdf
|
Calliditas
Therapeutics™ nomination committee for the AGM 2022
|
View original
content:https://www.prnewswire.com/news-releases/calliditas-therapeutics-nomination-committee-for-the-agm-2022-301413840.html
SOURCE Calliditas Therapeutics